Agilent Technologies Inc (A) Stock Up 3.1% and Still Undervalued -- GF Score: 93/100

FierceBiotechTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases

Endpoints NewsMale contraception startup closes $92.5M Series B; Novartis bets on actinium

Endpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipeline

Endpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after Carvykti

FierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

FierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push

PharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next

BioWorldJanssen Pharmaceutica reports new TMEM175 activators

BioWorldBlossomhill Therapeutics discovers new EGFR mutant inhibitors

BioWorldChina Pharmaceutical University discloses new asiaticoside saponin compounds

BioWorldWigen Biomedicine Technology patents new GTPase KRAS inhibitors

LabiotechThe biggest biotech funding rounds in May 2026